GMP News No. 335
6 August 2003
Will the GMP Regulations Be Harmonised Worldwide?
For a long time, the worldwide harmonisation of the GMP requirements seemed inconceivable. But now, this idea is not so unthinkable any more.
Many will find it astonishing that such an initiative comes from the FDA. We have already reported several times about the FDA reform "cGMP for the 21st Century." Some people may just have seen it as a normal improvement process of an authority. However, the actual consequences of this initiative will now also become clear to the last remaining sceptics.
The initiative, about which we reported in our News of 4 September 2002, has been established in order to review and revise the now almost 25-year-old GMP regulations fundamentally. The Risk-based Approach, as it is called, is at the heart of this initiative. By means of this approach, the FDA intends to coordinate all of its activities, e.g. the creation of guidelines, but also the conduct of inspections. In the interest of patient safety, special focus is now to be placed on those processes that involve a high risk for the patient. This means that the regulations will certainly place more emphasis e.g. on aseptic processing rather than on classic solid dosage forms manufacture for a generic drug.
The FDA does not see this initiative as
an isolated activity. The Agency also intends to introduce this approach
into international harmonisation. It aims at harmonising inspections and
regulations and thus at increasing patient safety while reducing costs. To
reach this aim, the FDA intends to harmonise the GMP requirements in
important areas via the International
Conference on Harmonisation (ICH). With ICH Q7A, there are already GMP
regulations (GMP for active pharmaceutical ingredients) that have been
harmonised worldwide. The other harmonised regulations in the triad
consisting of Europe, Japan, and the USA concern mainly the registration
of medicinal products. At the moment, the FDA is investigating whether it
should join the Pharmaceutical Inspection Convention Scheme (PIC/S). Only
few months ago, this would have been absolutely unthinkable. But the first
steps that have been taken leave no room for doubt.
Ms Showalter, ICH Coordinator of FDA: "The way we are going to do the meeting today, we are
going to go through some of the big topics for the Brussels meeting. One
of the big items on the agenda is actually the ICH portion of the GMP
Program, the Drug Product Quality, or GMP, Program for the 21st Century."
The FDA already presented its approach at the preparation meeting in Brussels for the coming ICH6 Conference, where it fell on sympathetic ears. In the minutes of the ICH Meeting from 15 to 18 July, it says:
The Steering Committee was pleased to hear
the positive outcome of a brainstorming workshop on initiatives related to
a risk-based approach to Drug Product Quality. This session was attended
by more than 60 designated experts from the six ICH parties, observers and
non-ICH parties. The workshop discussion led to a general agreement on a
high level vision: a harmonized pharmaceutical quality system applicable
across the lifecycle of the product emphasizing an integrated approach to
The Steering Committee agreed that the experts from the six parties will work further on two areas:
Industry will, in addition, produce a Quality Systems Scoping Document including GMP as a subset, which should address areas of perceived differences in the three regions.
It was also agreed to include a one-hour session of presentations on these GMP-related discussions and initiatives in the programme of the ICH6 Conference.
And what does the industry think about it? It is positively surprised! It considers the new FDA Initiative "cGMP for the 21st Century" as an extraordinary chance to harmonise the requirements and to focus them on the risk for the patient. Within the shortest possible time, EFPIA, the European Federation of Pharmaceutical Industries and Associations, has produced a separate paper on this subject. Here just a brief excerpt that shows how positive EFPIA's reaction to this FDA initiative was:
EFPIA welcomes the FDA's initiative to develop regulations and guidelines that would result in advancing scientifically sound and integrated systems, applicable to ensuring pharmaceutical product quality. EFPIA also appreciates the chance to comment on the concept paper and to participate in further discussion at the ICH meeting in Brussels in July 2003.
One essential aspect of the FDA's cGMP
Initiative is Process Analytical Technology (PAT). On behalf of the
University of Heidelberg, the European Conference and Workshop
The most-discussed GMP requirements that
differ between Europe and the US are those on electronic records and
signatures. Especially for the implementation in the laboratory, both the
EU-GMP and the FDA requirements are examined at the European Conference
As mentioned above, ICH Q7A (GMP
for active pharmaceutical ingredients) is the first GMP guideline that has
been harmonised. It will be one of the topics of the
Since its foundation, the European Compliance Academy (ECA) has been focusing its activities on imparting both the EU GMP requirements and the FDA cGMP requirements. Now it turns out that ECA's decision was, and still is, pointing the way ahead!